scholarly journals Introduction and clearance of beta‐glucan in the downstream processing of monoclonal antibodies

2021 ◽  
Author(s):  
Simon Kluters ◽  
Karin Steinhauser ◽  
Roland Pfänder ◽  
Joey Studts
Keyword(s):  
Monoclonal Antibodies ◽  
Downstream Processing ◽  
Beta Glucan

scholarly journals Sustainable strategies based on glycine–betaine analogue ionic liquids for the recovery of monoclonal antibodies from cell culture supernatants

2019 ◽  
Vol 21 (20) ◽  
pp. 5671-5682 ◽  
Author(s):  
Emanuel V. Capela ◽  
Alexandre E. Santiago ◽  
Ana F. C. S. Rufino ◽  
Ana P. M. Tavares ◽  
Matheus M. Pereira ◽  
...  
Keyword(s):  
Cell Culture ◽  
Monoclonal Antibodies ◽  
Downstream Processing ◽  
Aqueous Biphasic Systems ◽  
Phase Partitioning ◽  
Hybrid Processes ◽  
Three Phase ◽  
Aqueous Biphasic ◽  
Biphasic Systems ◽  
Culture Supernatants

Ionic-liquid-based aqueous biphasic systems, three phase partitioning methods and hybrid processes combined with ultrafiltration are sustainable strategies for the downstream processing of monoclonal antibodies.

scholarly journals Development of downstream processing to minimize beta-glucan impurities in GMP-manufactured therapeutic antibodies

2016 ◽  
Vol 32 (6) ◽  
pp. 1494-1502 ◽  
Author(s):  
Kim Vigor ◽  
John Emerson ◽  
Robert Scott ◽  
Julia Cheek ◽  
Claire Barton ◽  
...  
Keyword(s):  
Downstream Processing ◽  
Therapeutic Antibodies ◽  
Beta Glucan

Multimodal chromatography: debottlenecking the downstream processing of monoclonal antibodies

2015 ◽  
Vol 3 (3) ◽  
pp. 263-279 ◽  
Author(s):  
Inês F Pinto ◽  
Maria Raquel Aires-Barros ◽  
Ana M Azevedo
Keyword(s):  
Monoclonal Antibodies ◽  
Downstream Processing ◽  
Multimodal Chromatography

Downstream processing of monoclonal antibodies—Application of platform approaches

2007 ◽  
Vol 848 (1) ◽  
pp. 28-39 ◽  
Author(s):  
Abhinav A. Shukla ◽  
Brian Hubbard ◽  
Tim Tressel ◽  
Sam Guhan ◽  
Duncan Low
Keyword(s):  
Monoclonal Antibodies ◽  
Downstream Processing

scholarly journals Adaptation of Cholesterol Requiring NS0 Cells to Serum Free Culture Conditions

2011 ◽  
Vol 12 (4) ◽  
Author(s):  
Junaid Muneer Raja ◽  
Nurina Anuar ◽  
And Badarulhisam Abdul Rahman
Keyword(s):  
Cell Culture ◽  
Monoclonal Antibodies ◽  
Mammalian Cells ◽  
Culture Medium ◽  
Downstream Processing ◽  
Western World ◽  
Human Consumption ◽  
Cell Culture Medium ◽  
Serum Free ◽  
Ns0 Cells

Colorectal cancer is the third most common form of cancer and the second leading cause of cancer-related death in the Western world. The answers to such life threatening diseases and cancers are monoclonal antibodies (MAb's) which are widely used as therapeutic agents. World demand for currently approved MAb's is on the order of a few kilograms per year. However, new therapeutic MAb's are under development and require doses of several hundred milligrams to a gram over the course of therapy. Very often to cater for the special requirements for the growth of mammalian cells, serum is added to the cell culture medium. However, removal of serum from the cell culture medium is often carried out, especially if the end product is to be used for human consumption, in order to eliminate various disadvantages such as high physiological variability, high batch to batch variability, risk of contamination and high cost, and challenges posed in the downstream processing of the product. In this paper, the adaptation of cholesterol requiring NS0 cells to commercially available serum free media is presented. ABSTRAK: Kanser kolorektum merupakan kanser ketiga paling umum dan kini berada di tempat kedua penyebab kematian berkaitan kanser di negara Barat. Jawapan kepada penyakit yang mengancam nyawa dan penyakit kanser adalah antibodi monoklon (monoclonal antibodies ((MAb's)) yang digunakan sebagai agen terapeutik. Permintaan dunia terhadap MAb's yang diluluskan adalah dalam bilangan beberapa kilogram setahun. Namun, terapeutik MAb's yang baru adalah di bawah penyelidikan dan memerlukan beberapa ratus dos milligram hingga satu gram dalam satu peringkat terapi. Sering kali untuk memenuhi permintaan terhadap tumbesaran sel mamalia, serum dicampurkan dengan sel kultur perantara. Walaupun begitu, pemindahan serum dari sel kultur perantara sering dilakukan, terutamanya jika produk akhir digunakan untuk kegunaan manusia; untuk mengurangkan pelbagai kelemahan seperti kebolehubahan psikologi yang tinggi, kebolehubahan yang tinggi daripada satu kumpulan ke satu kumpulan lain, risiko pencemaran, kos yang tinggi, dan cabaran mendatang dalam pemprosesan produk. Dalam perbentangan ini, kolestrol yang diubah memerlukan sel NS0 yang dikomersilkan dengan serum bebas perantara.

Modeling the Downstream Processing of Monoclonal Antibodies Reveals Cost Advantages for Continuous Methods for a Broad Range of Manufacturing Scales

2018 ◽  
Vol 14 (2) ◽  
pp. 1700665 ◽  
Author(s):  
Jonathan Hummel ◽  
Mark Pagkaliwangan ◽  
Xhorxhi Gjoka ◽  
Terence Davidovits ◽  
Rick Stock ◽  
...  
Keyword(s):  
Monoclonal Antibodies ◽  
Downstream Processing ◽  
Continuous Methods

Design and scaleup of downstream processing of monoclonal antibodies for cancer therapy: from research to clinical proof of principle

2003 ◽  
Vol 275 (1-2) ◽  
pp. 99-112 ◽  
Author(s):  
Alberto L Horenstein ◽  
Federico Crivellin ◽  
Ada Funaro ◽  
Marcela Said ◽  
Fabio Malavasi
Keyword(s):  
Monoclonal Antibodies ◽  
Cancer Therapy ◽  
Downstream Processing ◽  
Proof Of Principle
Sign in / Sign up

Export Citation Format

Share Document